Paying users zone. Data is covered by 
.
Get 1-month access to Bristol-Myers Squibb Co. for $17.99, or
get full access to entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Bristol-Myers Squibb Co. (BMY)
Common-Size Income Statement
Difficulty: Beginner
Bristol-Myers Squibb Co., common-size consolidated income statement
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
| Income statement item | Description | The company |
|---|---|---|
| Operating income | The net result for the period of deducting operating expenses from operating revenues. | Bristol-Myers Squibb Co.’s operating income as a percentage of revenues declined from 2016 to 2017 but then increased from 2017 to 2018 not reaching 2016 level. |
| Earnings before income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Bristol-Myers Squibb Co.’s earnings before income taxes as a percentage of revenues declined from 2016 to 2017 but then slightly increased from 2017 to 2018. |
| Net earnings attributable to BMS | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Bristol-Myers Squibb Co.’s net earnings attributable to BMS as a percentage of revenues declined from 2016 to 2017 but then increased from 2017 to 2018 not reaching 2016 level. |